Combined Intravenous Diazepam, Local Periprostatic Nerve Block for Prostate Biopsy

Model scores of the 29,894 trials active now.

Model score 8% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 21% of the time (131 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Minimum age: 40 (lowers risk) · Who can join
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: cancereffectivetherapybiopsyintravenous
  Phrases that lowered it: painprocedureasthmaprostategel
• Primary purpose: prevention (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Maximum age: 95 (lowers risk) · Who can join
• Number of arms: 3 (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Phase: 2/3 (lowers risk) · Design
• Drug's FAERS reports with a death: 17.5% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor's past trials: 13 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 50787 (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 11 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sex: male (lowers risk) · Who can join
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial NCT06661902 · started 2025 · scored riskier than 75% of active trials completed
• Efficacy of Diclofenac Suppository for Pain Control in Ultrasound Guided Biopsy of Prostate NCT01939743 · started 2011 · scored riskier than 11% of active trials completed
• Trial of Methoxyflurane With Periprostatic Local Anaesthesia to Reduce the Discomfort of TRUS B NCT02604225 · started 2015 · scored riskier than 52% of active trials completed
• Mixture Nitrous Oxide - Oxygen 50-50% in Transrectal Prostate Biopsy Guided by Ultrasound NCT02899182 · started 2016 · scored riskier than 9% of active trials completed
• Targeted Fusion Biopsy of the Prostate NCT02744534 · started 2015 · scored riskier than 78% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.